Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth with R&D in Idiopathic Membranous Nephropathy
Idiopathic
membranous nephropathy a glomerular disease usually of abrupt onset and
associated with the nephrotic syndrome. Membranous nephropathy occurs when the
small blood vessels in the kidney (glomeruli), which filter wastes from the
blood, become damaged and thickened. As a result, proteins leak from the
damaged blood vessels into the urine (proteinuria).
R&D
in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic
membranous nephropathy treatment market. In July 2019, the study, ‘Rituximab or
Cyclosporine in the Treatment of Membranous Nephropathy’ stated that rituximab as
effective as cyclosporine in inducing complete or partial remission of
proteinuria at 12 months and was superior in maintaining proteinuria remission
up to 24 months.
Most
leading manufactures in the idiopathic
membranous nephropathy treatment market
are involved in the production of medicines for treatment of idiopathic
membranous nephropathy. Recent clinical trials have shown that medicines which
act on the musculoskeletal system can provide a rapid relief of symptoms in
patients with mild to moderate nephrolithiasis. Advancing research and
developments in this area is anticipated to support the worldwide, large-scale,
commercialize idiopathic membranous nephropathy treatment market. In November
2019, Novartis Pharmaceuticals imitated a randomized
study evaluating the efficacy and safety of LNP023 compared with rituximab in
subjects with membranous nephropathy who are at high risk of disease
progression defined on the basis of antibody anti-PLA2R titre and proteinuria.
The
idiopathic membranous nephropathy
treatment market in Asia Pacific is also driven by R&D of new drugs. In
June 2018, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, initiated
a random trial to assess the urine protein remission rate of tacrolimus
monotherapy for idiopathic membranous nephropathy. In December 2020, ValenzaBio,
a privately-held biopharmaceutical company developing therapies for autoimmune
and inflammatory diseases, initiated a Phase 1b/2a, open-label,
sequential-cohort, dose escalation, and dose expansion study to evaluate the
safety, tolerability, PK, and PD of VB119 in subjects with primary membranous
nephropathy. VB119 is a humanized,
immunoglobin (Ig) G1 monoclonal antibody (mAb) that can be administered as
intravenous infusion at multiple timepoints during the study.
In
November 2020, Hoffmann-La Roche, a major player in the idiopathic membranous
nephropathy treatment market, initiated a study to evaluate the efficacy,
safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared
with tacrolimus in participants with primary membranous nephropathy.
Comments
Post a Comment